Anti-EGFR VHHs linked to a CPP (non-arginine) resulted in 1000 fold higher cytotoxic activity in tumor cells compared to the small molecular EGFR tyrosine kinase inhibitors in preclinical experiments (126). Here, EGFR is linked to neoplasm.